Pharma Giant's TB Drug Decision Welcomed, But Not All Developing Countries Benefit

BRATISLAVA, Jul 21 (IPS) - In a surprise move, pharma giant Johnson and Johnson (J&J) has agreed not to enforce some of its patents on a lifesaving TB drug, making generic versions available in many low- and middle-income countries (LMICs).

Related Keywords

Johannesburg ,Gauteng ,South Africa ,Belarus ,Bratislava ,Bratislavsky Kraj ,Slovak Republic ,Russia ,Russian ,South African ,Christophe Perrin ,Priashni Subrayen ,Lindsay Mckenna ,Alena Skrahina ,Abhijit Bhattacharya ,Phumeza Tisile ,Treatment Action Group ,Eastern Coalfields Ltd ,Tb Partnership ,Ips Un Bureau ,Deputy National Tb Programme ,Aurum Institute ,Tb Project Co ,Central Hospital Kalla ,Global Drug Facility ,Medicins Sans Frontieres ,Eastern European ,Central Asian ,Deputy National ,Health ,Humanitarian Emergencies ,Asia Pacific ,Europe ,Frica ,Lobal ,Ed Holt ,Nter Press Service ,Lobal Issues ,